See more : Sindhu Trade Links Limited (SINDHUTRAD.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Swedish Orphan Biovitrum AB (publ) (BIOVF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Swedish Orphan Biovitrum AB (publ), a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- PT Bank China Construction Bank Indonesia Tbk (MCOR.JK) Income Statement Analysis – Financial Results
- PEDEVCO Corp. (PED) Income Statement Analysis – Financial Results
- Orange Electronic Co., Ltd. (4554.TWO) Income Statement Analysis – Financial Results
- Motorola Solutions, Inc. (MSI) Income Statement Analysis – Financial Results
- Aberforth Split Level Income Trust PLC (ASIT.L) Income Statement Analysis – Financial Results
Swedish Orphan Biovitrum AB (publ) (BIOVF)
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.12B | 18.79B | 15.53B | 15.26B | 14.25B | 9.14B | 6.51B | 5.20B | 3.23B | 2.61B | 2.18B | 1.92B | 1.91B | 1.91B | 1.30B | 1.14B | 1.26B | 1.20B | 936.61M | 645.29M | 1.66B | 1.30B |
| Cost of Revenue | 5.00B | 4.78B | 3.48B | 3.23B | 3.34B | 2.42B | 1.85B | 1.55B | 1.22B | 1.06B | 892.73M | 882.78M | 936.26M | 685.70M | 375.74M | 264.66M | 348.77M | 293.81M | 270.66M | 248.32M | 611.98M | 596.87M |
| Gross Profit | 17.13B | 14.01B | 12.05B | 12.04B | 10.91B | 6.72B | 4.66B | 3.65B | 2.01B | 1.55B | 1.28B | 1.04B | 974.57M | 1.22B | 921.23M | 875.92M | 907.66M | 907.29M | 665.95M | 396.96M | 1.05B | 704.82M |
| Gross Profit Ratio | 77.42% | 74.58% | 77.56% | 78.87% | 76.59% | 73.57% | 71.52% | 70.14% | 62.17% | 59.37% | 58.99% | 54.10% | 51.00% | 64.04% | 71.03% | 76.80% | 72.24% | 75.54% | 71.10% | 61.52% | 63.08% | 54.15% |
| Research & Development | 2.80B | 2.35B | 1.99B | 1.59B | 1.50B | 1.09B | 907.72M | 777.59M | 513.37M | 500.49M | 455.69M | 401.65M | 555.72M | 479.80M | 569.42M | 670.56M | 694.35M | 650.35M | 576.00M | 534.70M | 583.17M | 568.73M |
| General & Administrative | 10.16B | 7.85B | 6.29B | 5.98B | 0.00 | 0.00 | 1.28M | 2.32M | 3.46M | 3.66M | 3.38M | 4.25M | 804.46M | 479.80M | 193.30M | 216.18M | 77.38M | 77.36M | 151.23M | 129.18M | 114.99M | 139.97M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 4.94B | 2.51B | 2.10B | 1.78B | 1.34B | 1.03B | 898.23M | 961.14M | 0.00 | 825.70M | 109.61M | 51.78M | 43.72M | 41.59M | 38.66M | 34.51M | 37.18M | 58.21M |
| SG&A | 10.16B | 7.85B | 6.29B | 5.98B | 4.94B | 2.51B | 2.10B | 1.78B | 1.35B | 1.04B | 901.60M | 965.39M | 804.46M | 1.31B | 302.90M | 267.96M | 121.10M | 118.95M | 189.90M | 163.69M | 152.16M | 198.17M |
| Other Expenses | 105.00M | -32.00M | -30.00M | -2.00M | -16.00M | 0.00 | 471.00K | 1.70M | 236.00K | 781.00K | 2.73M | 8.84M | 0.00 | 0.00 | 0.00 | -380.10M | 1.03M | 266.00K | -402.49M | 23.28M | -393.65M | 22.67M |
| Operating Expenses | 13.06B | 10.17B | 8.26B | 7.57B | 6.41B | 3.60B | 3.01B | 2.55B | 1.86B | 1.53B | 1.36B | 1.36B | 1.16B | 1.14B | 948.32M | 11.73M | 850.49M | 802.81M | 393.38M | 339.54M | 985.56M | 660.71M |
| Cost & Expenses | 18.06B | 14.95B | 11.74B | 10.80B | 9.75B | 6.01B | 4.86B | 4.11B | 3.08B | 2.59B | 2.25B | 2.24B | 2.10B | 1.83B | 1.32B | 276.40M | 1.20B | 1.10B | 664.05M | 587.86M | 1.60B | 1.26B |
| Interest Income | 27.00M | 5.00M | 419.00M | 1.00M | 5.00M | 2.74M | 1.22M | 1.43M | 2.93M | 4.23M | 4.49M | 2.33M | 10.50M | 4.73M | 28.60M | 1.22M | 3.01M | 2.37M | 1.58M | 358.00K | 924.00K | 8.32M |
| Interest Expense | 1.11B | 458.00M | 0.00 | 454.00M | 241.00M | 56.46M | 63.97M | 78.55M | 54.71M | 56.62M | 60.41M | 42.25M | 62.73M | 77.44M | 12.34M | 21.42M | 450.00K | 262.00K | 49.43M | 52.22M | 36.84M | 39.26M |
| Depreciation & Amortization | 3.17B | 2.27B | 2.00B | 2.02B | 1.51B | 484.57M | 473.98M | 440.71M | 318.99M | 581.55M | 307.62M | 454.30M | 140.59M | 175.40M | 28.60M | -378.88M | 70.49M | 74.54M | -400.92M | 23.63M | -392.72M | 30.99M |
| EBITDA | 7.23B | 6.05B | 5.72B | 6.69B | 6.08B | 3.62B | 2.08B | 1.57B | 461.39M | 319.60M | 240.26M | 391.45M | -38.53M | 165.20M | 44.78M | -364.78M | 155.46M | 168.99M | -128.35M | -40.00M | -332.89M | 75.10M |
| EBITDA Ratio | 32.70% | 32.99% | 37.19% | 41.26% | 42.41% | 39.64% | 31.98% | 30.03% | 14.29% | 25.69% | 11.04% | 6.30% | -9.32% | 8.66% | 3.45% | -30.21% | 12.37% | 17.76% | -13.70% | 12.56% | -20.09% | 5.77% |
| Operating Income | 4.07B | 3.81B | 3.73B | 4.82B | 4.53B | 3.12B | 1.60B | 1.13B | 146.04M | -324.98M | -66.53M | -54.61M | -318.62M | -10.20M | 16.17M | 34.30M | 55.12M | 54.59M | 272.56M | 57.43M | 59.84M | 44.11M |
| Operating Income Ratio | 18.38% | 20.29% | 24.04% | 31.57% | 31.81% | 34.16% | 24.58% | 21.77% | 4.52% | -12.47% | -3.06% | -2.84% | -16.67% | -0.53% | 1.25% | 3.01% | 4.39% | 4.54% | 29.10% | 8.90% | 3.61% | 3.39% |
| Total Other Income/Expenses | -1.11B | -492.00M | -438.00M | -601.00M | -286.00M | -40.00M | -73.69M | -50.16M | -57.83M | -336.58M | -56.88M | -24.97M | -52.23M | -82.17M | 16.14M | -400.30M | 23.87M | 39.60M | -450.35M | -28.59M | -429.57M | -8.27M |
| Income Before Tax | 2.95B | 3.32B | 3.30B | 4.22B | 4.25B | 3.08B | 1.53B | 1.05B | 87.69M | -318.57M | -123.42M | -105.09M | -370.85M | -92.40M | 32.44M | -366.00M | 78.99M | 94.19M | -177.78M | 28.84M | -369.73M | 35.84M |
| Income Before Tax Ratio | 13.35% | 17.67% | 21.22% | 27.63% | 29.81% | 33.72% | 23.54% | 20.14% | 2.72% | -12.22% | -5.67% | -5.46% | -19.41% | -4.85% | 2.50% | -32.09% | 6.29% | 7.84% | -18.98% | 4.47% | -22.31% | 2.75% |
| Income Tax Expense | 546.00M | 683.00M | 616.00M | 972.00M | 942.00M | 663.94M | 383.81M | 238.91M | 19.30M | -50.73M | -30.46M | -4.21M | -388.77M | 12.00M | 0.00 | -30.64M | 1.00K | 1.52M | 1.00M | -2.35M | -739.46M | 1.00K |
| Net Income | 2.41B | 2.64B | 2.68B | 3.25B | 3.30B | 2.42B | 1.15B | 809.07M | 68.39M | -267.83M | -92.96M | -100.88M | 17.93M | -104.40M | 32.44M | -335.36M | 78.98M | 92.67M | 176.22M | -26.49M | 369.73M | -35.85M |
| Net Income Ratio | 10.89% | 14.04% | 17.25% | 21.26% | 23.19% | 26.46% | 17.64% | 15.55% | 2.12% | -10.27% | -4.27% | -5.25% | 0.94% | -5.48% | 2.50% | -29.40% | 6.29% | 7.72% | 18.81% | -4.11% | 22.31% | -2.75% |
| EPS | 7.39 | 8.52 | 8.67 | 10.52 | 10.78 | 8.93 | 4.27 | 3.01 | 0.26 | -1.01 | -0.35 | -0.38 | 0.07 | -0.53 | 0.57 | -3.00 | 0.78 | 0.90 | 1.73 | -0.26 | 3.63 | -0.35 |
| EPS Diluted | 7.39 | 8.44 | 8.62 | 10.41 | 10.72 | 8.93 | 4.25 | 3.01 | 0.26 | -1.01 | -0.35 | -0.38 | 0.07 | -0.52 | 0.57 | -3.00 | 0.76 | 0.83 | 1.73 | -0.26 | 3.63 | -0.35 |
| Weighted Avg Shares Out | 325.98M | 309.48M | 308.90M | 308.49M | 306.38M | 270.60M | 269.02M | 268.36M | 267.28M | 265.18M | 265.27M | 265.23M | 242.12M | 198.74M | 56.42M | 111.91M | 101.82M | 103.39M | 101.82M | 101.82M | 101.82M | 101.82M |
| Weighted Avg Shares Out (Dil) | 325.97M | 312.46M | 310.73M | 311.61M | 308.35M | 270.60M | 270.00M | 269.22M | 267.28M | 266.16M | 265.27M | 265.23M | 242.12M | 199.37M | 56.97M | 111.91M | 104.54M | 111.27M | 101.82M | 101.82M | 101.82M | 101.82M |
Is Swedish Orphan Biovitrum (BIOVF) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Bulletin from Swedish Orphan Biovitrum (Sobi)'s Extraordinary General Meeting (EGM)
STOCKHOLM, Sweden , Aug. 15, 2023 /PRNewswire/ -- The Sobi® EGM was convened today on 15 August 2023. At the EGM, the shareholders, in accordance with the proposed resolutions, resolved as follows: Authorisation for the Board of Directors to resolve on...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2023 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q2 2023 Results Conference Call July 18, 2023 7:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financial Officer Armin Reininger - Senior Scientific and Medical Officer Conference...
Swedish Orphan Biovitrum (BIOVF) Beats Q2 Earnings and Revenue Estimates
Swedish Orphan Biovitrum (BIOVF) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.09 per share a year ago.
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
STOCKHOLM , July 18, 2023 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting (the "Meeting"), to be held on Tuesday, 15 August 2023 at 10.00 at...
Swedish Orphan Biovitrum (BIOVF) Earnings Expected to Grow: Should You Buy?
Swedish Orphan Biovitrum (BIOVF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion
Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a deal valued at $1.7 billion. The Stockholm-based drugmaker said it will offer $9.10 for each share...
Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE...
Sobi to Acquire CTI BioPharma
Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE , May 10, 2023 /PRNewswire/ -- CTI BioPharma (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2023 Earnings Call Transcript
Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q1 2023 Earnings Conference Call April 27, 2023 8:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financial Officer Tony Hoos - Head of RDMA, Chief Medical Officer...
Source: https://incomestatements.info
Category: Stock Reports